Global Information
회사소개 | 문의 | 비교리스트

인도의 의약품 시장 예측(2019-2029년)

Indian Pharmaceutical Market Forecast 2019-2029

리서치사 Visiongain Ltd
발행일 2019년 05월 상품 코드 346223
페이지 정보 영문 212 Pages
가격
£ 3,499 ₩ 5,530,000 Unprintable PDF (Single User) - 1 Year License help
1명만 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC 1대에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄 또한 불가능합니다.
£ 3,899 ₩ 6,162,000 PDF (Departmental - 5 Users) - 1 Year License help
동일 사업장(소재지) 내 5명까지 이용할 수 있는 라이센스입니다. DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 인증된 PC에서만 열람이 가능하며, 구입일로부터 1년간 유효합니다. PDF파일은 Copy & Paste가 되지 않으며, 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 4,999 ₩ 7,901,000 PDF (Site License) help
동일 사업장(소재지) 내 모든 분이 이용할 수 있는 라이센스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 되지 않습니다. DRM(디지털 저작권 관리시스템)은 적용되어 있지 않지만, PDF 인쇄는 1명당 1회에 한해 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
£ 6,999 ₩ 11,062,000 PDF (Global License - Includes Free Datasets)

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



인도의 의약품 시장 예측(2019-2029년) Indian Pharmaceutical Market Forecast 2019-2029
발행일 : 2019년 05월 페이지 정보 : 영문 212 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

인도의 의약품 시장은 2018년에 288억 달러에 달했으며, 2019-2024년간 16.6%의 연평균 성장률(CAGR)로 계속 성장할 전망입니다. 특히 심혈관 질환 및 감염증 치료제의 수요가 향후 크게 증가할 것으로 보입니다.

인도의 의약품(Pharmaceutical) 시장에 대해 조사 분석했으며, 시장의 기본 구조와 배경, 매출 동향 예측, 주요 기업 평가, 성장 촉진요인과 억제요인, 전망 등 체계적인 정보를 제공합니다.

제1장 보고서 개요

제2장 인도의 의료 : 개요

  • 인도 : 인구통계 지표 개요
  • 인도의 의료제도 : 개요
    • Rashtriya Swasthya Bima Yojana : 극빈 노동자용 의료보험 제공
  • 인도의 의료비 분석

제3장 인도의 의약품 규제 체제

  • 규제기관
    • 보건복지부(MoHFW)
    • 화학비료부(MoC&F)
  • 정부 관련 기관
  • 인도의 의약품 시장용 법령과 규제 : 리스트
  • 시장 접근
    • 의료제도
    • HTA(Health Technology Assessment) 현황
    • 약가 동향
    • 의약품의 의료비 상환

제4장 인도의 의약품 시장 : 논의와 예측

  • 세계에서 3번째로 큰 시장
  • 시장 매출 예측(총액, 향후 12년간)

제5장 인도의 의료 요구

  • 각종 질환의 유병자수(향후 11년간)
  • 각종 질환의 발증건수(향후 11년간)
  • 각종 질환의 사망률(향후 11년간)
    • 인도의 주요 사인
    • 주요 사인 : 사망률 예측(향후 11년간)

제6장 인도의 의약품 시장 : 주요 치료 분야

  • 주요 치료 분야 : 개요
  • 시장 예측 : 주요 치료 분야별(향후 11년간)
  • 감염증 치료제
    • 시장 예측(향후 11년간)
      • 설사
      • 하기도감염
      • 결핵
      • 말라리아
      • HIV
    • 시장 성장 촉진·억제요인
  • 심혈관 질환 치료제
  • 위장 질환 치료제
  • 호흡기 질환 치료제
  • 통증완화제/진통제
  • 당뇨병 치료제
  • 비타민/미네랄/영양제
  • 피부병 치료제
  • 중추신경계(CNS) 질환 치료제
  • 부인과 질환 치료제
  • 기타 질환 치료제

제7장 인도의 의약품 시장 : 주요 약제 종류

  • 인도 시장의 의약품 종류 : 개요
  • 주요 의약품 종류의 성장률 예측(향후 11년간)
  • 제네릭 의약품 - 인도 시장의 대부분을 차지하는 존재
    • 시장 예측(향후 11년간)
    • 시장 성장 촉진·억제요인 등
  • OTC 의약품(시판약)
  • 특허 의약품
  • 바이오시밀러 의약품

제8장 인도 의약품 시장의 대표적 기업

  • 인도의 의약품 시장 : 개요
    • 인도의 의약품 관련 특허법과 대형 제약 기업에 대한 영향력
  • 인도의 제약 기업 상위 50개사
  • Sun Pharmaceuticals Industries Limited
    • 실적 동향(과거 10년간)
    • 사업 추진/자본 거래 동향
  • Abbott Healthcare Private Limited(Abbott India)
  • Cipla Ltd.
  • Cadila Healthcare Limited
  • GlaxoSmithKline Pharmaceuticals Limited
  • Pfizer Limited., India
  • Lupin
  • Sanofi India Limited
  • Intas Pharmaceuticals Limited
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Limited

제9장 인도 의약품 시장의 정성 분석

  • 인도의 의약품 시장 : 성장 촉진·억제요인
  • 인도의 의약품 시장 SWOT 분석
  • 강점
    • 의료 제도에 대한 투자 확대
    • 질병 부담 및 GDP 증가
    • 인도의 총인구 : 2030년에는 세계 최대가 된다
    • 제약 산업의 외주처로서 유망한 인도
  • 약점
    • 엄격한 가격 규제의 시장에 대한 악영향
    • 빈약한 의료 인프라에 의한 잠재적 시장 축소
    • 경쟁 격화에 따른 약가 하락
  • 기회
    • 세계 규모에서의 제네릭 의약품 수요 증가
    • 국가농촌의료활동(NRHM) : 농촌의 의료 접근성 개선
    • 다국적기업(MNC)에 의한 거액의 투자 전망
    • 혁신적인 바이오테크놀러지 부문 : 특허 만료를 기회로 약진
  • 위협
    • 제네릭 의약품 : 기타 저비용 수출국의 대두
    • 인도 정부는 향후에도 의료비 증액 경향을 유지하는가?
    • 당국으로부터의 최근 경고와 수출 금지령 : 제약 기업의 자신감 상실
  • Porter's Five Forces 분석
    • 기업간 경쟁(고)
    • 신규 진출 기업의 위협(저)
    • 공급업체의 협상력(중)
    • 구매자의 협상력(고)
    • 대체 제품의 위협(저)

제10장 결론

  • 인도의 의약품 시장 : 세계 시장에서의 점유율 확대
  • 만성 질환 환자의 급증
  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 분석 결과

제11장 용어

KSM 19.07.18

List of Tables

  • Table 4.1 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Table 5.2 Leading Types of Cancer in India by Age-Standardised Death Rate (per 100,000 People), 2014
  • Table 5.3 Causes of Death in India by World Ranking, 2014
  • Table 6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2018, 2024, 2029
  • Table 6.2 The Indian Pharmaceutical Market: Revenue ($bn), AGR (%) and CAGR (%) by Therapeutic Area, 2018-2029
  • Table 6.3 The Infectious Disease Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.4 The Indian Cardiovascular Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.5 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.6 The Indian Respiratory Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.7 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.8 Indian Diabetes Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.9 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.10 Indian Dermatological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.11 Indian CNS Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.12 Indian Gynaecological Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 6.13 Indian Other Therapeutics Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2019, 2024 and 2029
  • Table 7.2 Indian Pharmaceutical Market: Revenue ($bn), AGR (%), CAGR (%) by Drug Type, 2019-2029
  • Table 7.3 Indian Generic Drugs Market: Revenue ($bn), AGR (%) and CAGR (%) 2018-2029
  • Table 7.4 Indian OTC Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.5 Indian Patented Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.6 Selected Biosimilar Therapeutics on the Indian Market, 2018
  • Table 7.7 Indian Biosimilar Drugs Market: Revenue ($bn), AGR (%) and CAGR (%), 2018-2029
  • Table 7.8 Selected Blockbuster Biologic Patent Expiries in the US and EU, 2015-2028
  • Table 7.9 Selected Late-Stage Biosimilar Pipeline Products, 2015
  • Table 8.1 Top 50 Companies in the Indian Pharmaceutical Market: Revenue (Rs. m), Revenue ($m) and Market Share (%), 2017
  • Table 8.2 Sun Pharmaceuticals: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Business Area, FY 2017
  • Table 8.3 Sun Pharmaceuticals: Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.4 Sun Pharmaceuticals: M&A Activity, 1997-2016
  • Table 8.5 Abbott India: Market Share (%) and Market Rank of Key Brands
  • Table 8.6 Abbott India: Revenue (Rs. m), AGR (%) and CAGR (%), 2006-2017
  • Table 8.7 Cipla: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.8 Cipla: Revenue (Rs. m), Revenue ($m) and Revenue Share (%) by Geographical Area, 2017
  • Table 8.9 Cadila Healthcare Ltd.: Total Revenue (Rs. m), Total Revenue ($m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.10 Cadila Healthcare Ltd.: Revenue (Rs.m) and Revenue Share (%) by Therapeutic Area, 2017
  • Table 8.11 GlaxoSmithKline India: Key Products in the Indian Market, 2017
  • Table 8.12 GlaxoSmithKline India Total Revenue (Rs. m), AGR (%) and CAGR (%), 2007-2017
  • Table 8.13 Pfizer India: Leading Brands on the Indian Market 2017
  • Table 8.14 Pfizer India: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.15 Lupin: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.16 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Table 8.17 Sanofi India Limited: Major Products,2017
  • Table 8.18 Sanofi India Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.19 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Domestic Segment, 2017
  • Table 8.20 Sanofi India Limited: Revenue (Rs. m) and Revenue Share (%) by Branded drugs, 2017
  • Table 8.21 Sanofi India Limited: Revenue (Rs. m), and Revenue Share (%) by Geographical Area, 2017
  • Table 8.22 Intas Pharmaceuticals Limited: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.23 Dr. Reddy's Laboratories Ltd: Major Products,2017
  • Table 8.24 Dr. Reddy's Laboratories Ltd: Total Revenue (Rs. m), AGR (%) and CAGR (%), 2008-2017
  • Table 8.25 Dr. Reddy's Laboratories Ltd: Revenue (Rs. m), and Revenue Share (%) by Business Segment, 2017
  • Table 8.26 Dr. Reddy's Laboratories Ltd: Revenue (Rs.m), and Revenue Share (%) by Geographical Area, 2017
  • Table 8.27 Glenmark Pharmaceuticals Limited: Total Revenue (Rs.m), AGR (%) and CAGR (%), 2008-2017
  • Table 9.1 SWOT Analysis of the Indian Pharmaceuticals Market

List of Figures

  • Figure 1.1 Indian Pharmaceutical Market: Overview of Submarkets
  • Figure 2.1 Indian Population: Rural and Urban (Mn),1960-2020
  • Figure 2.2 Indian Population: Total (Mn) and Annual Population Growth Rate (%), 1960-2020
  • Figure 2.3 Indian GDP ($bn) and Growth Rate (%), 2010-2020
  • Figure 2.4 Access to Improved Water Sources as a Proportion of Total Population (%) and Access to Improved Sanitation as a Proportion of Total Population (%), 2008-2020
  • Figure 2.5 Indian GDP ($bn) and Health Expenditure as a Proportion of GDP (%), 2006-2014
  • Figure 2.6 Health Expenditure: Public Health expenditure as a Proportion of Total Health Expenditure (%) and Out of Pocket Expenditure as a Proportion of Private Health Expenditure 2008-2014
  • Figure 3.1 National Regulatory Bodies Regulating the Indian Pharmaceutical Market
  • Figure 4.1 The Indian Pharmaceutical Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 5.1 Leading Causes of Death in India, Proportion of Total Deaths (%) 2014
  • Figure 6.1 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2018
  • Figure 6.2 Leading Therapeutic Areas in the Indian Pharmaceuticals Market: Market Share (%), 2024
  • Figure 6.3 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Market Share (%), 2029
  • Figure 6.4 The Infectious Disease Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.5 Malaria cases (m), P. falciparum cases (m) and Proportion of P. falciparum cases (%) in India, 1995-2014
  • Figure 6.6 Infectious Diseases Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.7 The Indian Cardiovascular Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.8 Cardiovascular Diseases Therapeutics Market in India: Drivers and Restraints
  • Figure 6.9 Indian Gastro-Intestinal Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.10 Gastro-intestinal Therapeutics Market in India: Drivers and Restraints
  • Figure 6.11 Indian Respiratory Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.12 Respiratory Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.13 Indian Pain Relief/Analgesics Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.14 Pain Relief/Analgesics Therapeutics Market in India: Drivers and Restraints, 2018-2029
  • Figure 6.15 Indian Diabetes Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.16 Diabetes Therapeutics Market in India: Drivers and Restraints
  • Figure 6.17 Indian Vitamins / Minerals / Nutrients Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.18 Vitamins / Minerals / Nutrients Therapeutics Market in India: Drivers and Restraints
  • Figure 6.19 Indian Dermatological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.20 Dermatological Therapeutics Market in India: Drivers and Restraints
  • Figure 6.21 Indian CNS Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.22 CNS Therapeutics Market in India: Drivers and Restraints
  • Figure 6.23 Indian Gynaecological Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 6.24 Gynaecological Therapeutics Market in India: Drivers and Restraints
  • Figure 6.25 Indian Other Therapeutics Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.1 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2019
  • Figure 7.2 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2024
  • Figure 7.3 Leading Drug Types in the Indian Pharmaceutical Market: Market Share (%), 2029
  • Figure 7.4 Indian Generic Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.5 Generic Drugs Market in India: Drivers and Restraints
  • Figure 7.6 Indian OTC Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.7 OTC Drugs Market in India: Drivers and Restraints
  • Figure 7.8 Indian Patented Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.9 Patented Drugs Market in India: Drivers and Restraints
  • Figure 7.10 Indian Biosimilar Drugs Market: Revenue ($bn) and AGR (%), 2018-2029
  • Figure 7.11 Biosimilar Drug Market in India: Drivers and Restraints
  • Figure 8.1 Sun Pharmaceuticals: Revenue Share (%) by Business Area, FY 2017
  • Figure 8.2 Sun Pharmaceuticals: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.3 Abbott India: Revenue (Rs. m) and AGR (%), 2006-2017
  • Figure 8.4 Cipla Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 8.5 Cadila Healthcare Ltd.: Revenue Share (%), by Business Area, 2017
  • Figure 8.6 GlaxoSmithKline India: Revenue ($m) and AGR (%), 2007-2017
  • Figure 8.7 Pfizer India: Revenue (Rs.m) and AGR (%), 2007-2016
  • Figure 8.8 Lupin: Revenue (Rs.m) and AGR (%), 2008-2017
  • Figure 8.9 Lupin: Revenue Share (%) by Therapeutic Area, 2017
  • Figure 8.10 Sanofi India Limited: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.11 Sanofi India Limited: Revenue Distribution by Business Segments, 2017
  • Figure 8.12 Sanofi India Limited: Revenue Distribution by Domestic Segments, 2017
  • Figure 8.13 Sanofi India Limited: Revenue Distribution by Geographical Area, 2017
  • Figure 8.14 Intas Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.15 Dr. Reddy's Laboratories Ltd: Revenue ($m) and AGR (%), 2008-2017
  • Figure 8.16 Dr. Reddy's Laboratories Ltd: Revenue Distribution by Business Segments, 2017
  • Figure 8.17 Dr. Reddy's Laboratories Ltd: Global Generics Segment Revenue Distribution by Geographical Area, 2017
  • Figure 8.18 Glenmark Pharmaceuticals Limited: Revenue ($m) and AGR (%), 2007-2017
  • Figure 8.19 Glenmark Pharmaceuticals Limited: Revenue Distribution by Geographical Area, 2017
  • Figure 9.1 Indian Pharmaceuticals Market: Drivers and Restraints
  • Figure 9.2 Porter's Five Forces Analysis of the Indian Pharmaceuticals Market

COMPANIES LISTED:

  • Abbott India
  • Able Labs
  • Ajanta Pharma Ltd
  • Akumentis Healthcare Ltd
  • Albert David Ltd
  • Alembic
  • Alkem
  • Almirall
  • Amgen
  • Apex Laboratories Pvt. Ltd
  • Aristo Pharma
  • Ascendis Pharma
  • AstraZeneca
  • Aventis Pharma Limited
  • Bayer
  • Bharat Serums
  • Biocon Ltd
  • Biosintez
  • Blue Cross Laboratories Ltd.
  • Cadila Healthcare Ltd.
  • Caraco
  • Chattem Chemicals, Inc.
  • Cipla
  • Claris Lifesciences
  • Daiichi Sankyo
  • Divis Laboratories
  • Dr. Reddy's Laboratories
  • DUSA Pharma, Inc.
  • Eli Lilly and Company (India) Pvt. Ltd.
  • Emcare
  • Eris Lifesciences
  • Exelan
  • FDC
  • Fourrts (India) Laboratories Pvt, Ltd
  • Franco India
  • GlaxoSmithKline India
  • Glenmark Pharma
  • GSK India
  • Heinz India
  • Helsinn Group
  • Hetero Drugs Ltd
  • Hoechst India Limited
  • Hoechst Marion Roussel Limited
  • Hoechst Pharmaceuticals Private Limited
  • Indoco
  • Indi Pharma Pvt. Ltd.
  • InSite Vision
  • Intas Pharma
  • InvaGen
  • Ipca Laboratories
  • Janssen
  • JB Chemicals
  • JSC Biosintez
  • Lonza
  • Lupin
  • Macleods
  • MannKind Corporation
  • Medley Pharmaceuticals Ltd
  • MedproPhamaceutica (Pty) Ltd
  • Megafine Pharma
  • Merck KGaA
  • Meyer Organics
  • Micro Labs
  • MSD Pharma
  • Natco
  • Novartis India
  • Novo Nordisk
  • Odomzo
  • Pfizer India
  • Pharmalucence
  • Piramal Healthcare
  • Pola Pharma, Inc.
  • Ranbaxy
  • Raptakos, Brett & Co. Ltd
  • Roche Pharma India
  • Sandoz, Novartis Division
  • Sanofi India
  • Seciera
  • Sun Pharmaceuticals
  • Taro Pharmaceutical Industries Ltd.
  • Teva Pharmaceuticals (Pty)Ltd
  • The Himalaya Drug Company
  • Torrent Pharma
  • True North
  • Unichem
  • URL's
  • USV
  • Wallace Pharmaceuticals
  • Win-Medicare
  • Wockhardt
  • Wockhardt
  • Zydus Wellness Ltd

List of Organizations Mentioned in the Report:

  • Australia's TGA (Therapeutic Goods Administration)
  • Central Drugs Standard Control Organisation
  • Competition Commission of India (CCI)
  • Dr. M.G.R. Medical University (TNMGRMU)
  • Drug Consultative Committee
  • Drug Controller General of India
  • Medical Council of India
  • MHLW (Ministry of Health, Labour and Welfare)
  • MHRA (Medicines & Healthcare Products Regulatory Agency)
  • Ministry of Chemicals & Fertilisers
  • Ministry of Health and Family Welfare
  • National AIDS Control Organisation (NACO)
  • National Pharmaceutical Pricing Authority
  • Organisation for Economic Co-operation and Development (OECD)
  • State Food and Drug Administrations
  • The Joint United Nations Programme on HIV/AIDS (UNAIDS)
  • US Federal Trade Commission (FTC)
  • World Health Organization (WHO)

The Indian pharmaceuticals market is estimated to have reach $28.8bn in 2018 and is expected to grow at a CAGR of 16.6% in the first half of the forecast period. The market for cardiovascular medication is the fastest growing segment of the Indian pharmaceutical market, followed by the anti-infective segment.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 212-page report you will receive 121 charts - all unavailable elsewhere.

The 212-page report provides clear detailed insight into the Indian Pharmaceutical Market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Indian Pharmaceuticals Market forecasts from 2019-2029

Revenue forecasts for the leading therapeutic areas in India from 2019-2029:

  • Anti-Infectives Therapeutics
  • Cardiovascular Therapeutics
  • Dermatological Therapeutics
  • Diabetes Therapeutics
  • Gastrointestinal Therapeutics
  • Gynaecology Therapeutics
  • CNS Therapeutics
  • Pain Relief/Analgesics Therapeutics
  • Respiratory Therapeutics
  • Vitamins/Minerals/Nutrients Therapeutics
  • Other Therapeutics

This report also discusses factors that drive and restrain these submarkets.

Revenue forecasts for the leading drug types in India from 2019-2029:

  • Generic Drugs
  • Over-the-Counter (OTC) Drugs
  • Patented Drugs
  • Biosimilar Drugs

This report also discusses factors that drive and restrain these submarkets.

Profiles and discusses the leading companies in the Indian pharmaceutical market:

  • Abbott Healthcare Private Limited (Abbott India)
  • Cadila Healthcare Limited
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline Pharmaceuticals Limited
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Limited
  • Lupin
  • Pfizer Limited
  • Sanofi India Limited
  • Sun Pharmaceuticals Industries Limited

(Revenues are provided for those companies whose financial information is available on the public domain)

  • Analysis of the drivers and restraints of the Indian Pharmaceutical market
  • The report also discusses the Porter's Five Forces Analysis and SWOT Analysis of the Indian Pharmaceuticals Market

This report also discusses:

  • Indian healthcare system and Indian healthcare expenditure
  • Indian pharmaceutical regulatory framework, laws & regulations, market access, regulatory bodies
  • Disease prevalence and incidence in India, disease mortality rates in India, top causes of death in India, mortality projections from 2019-2029

What this report provides:

  • The Indian pharmaceutical market forecasts and analysis from 2019 to 2029
  • Analysis and forecasts for the Indian pharmaceutical submarkets from 2019 to 2029
  • Profiles of the leading companies operating within the Indian pharmaceutical industry
  • SWOT analysis and Porter's five forces analysis of the major strengths and weaknesses of the Indian pharmaceutical market together with the opportunities available and the key threats faced

Visiongain's study is intended for anyone requiring commercial analyses for the Indian Pharmaceuticals Market. You find data, trends and predictions.

Buy our report today Indian Pharmaceutical Market Forecast 2019-2029: Infectious Disease, Cardiovascular, Gastrointestinal, Respiratory, Pain Relief / Analgesics, Diabetes, Vitamins/ Minerals/ Nutrients, Dermatology, CNS, Gynaecology, Generic, OTC, Patented, Biosimilar, Leading Companies’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 The Indian Pharmaceutical Market Overview
  • 1.2 Indian Pharmaceutical Market Segmentation
  • 1.3 Why You Should Read This Report
  • 1.4 How This Report Delivers
  • 1.5 Key Questions Answered by This Analytical Report
  • 1.6 Who is This Report For?
  • 1.7 Methodology
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Reports
  • 1.10 About Visiongain

2. Indian Healthcare: Overview

  • 2.1 India: Demographic Indicators Overview
  • 2.2 Indian Healthcare System: Overview
    • 2.2.1 Rashtriya Swasthya Bima Yojana - Bringing Healthcare Coverage to India's Poorest Workers
  • 2.3 Analysis of India's Healthcare Expenditure

3. Indian Pharmaceutical Regulatory Framework

  • 3.1 National Regulatory Bodies
    • 3.1.1 Ministry of Health & Family Welfare (MoHFW)
    • 3.1.2 Ministry of Chemicals and Fertilizers (MoC&F)
  • 3.2 State Regulatory Bodies (State Food and Drug Administrations (FDAs)
  • 3.3 Laws & Regulations for Indian Pharmaceutical Market
    • 3.3.1 The Drugs and Cosmetics Act, 1940
    • 3.3.2 The Pharmacy Act, 1948
    • 3.3.3 The Drugs & Magic Remedies Act, 1954
    • 3.3.4 The Narcotic Drugs and Psychotropic Substances Act, (NDPS)1985
    • 3.3.5 The Medicinal and Toilet Preparations Act, 1956
    • 3.3.6 The Drugs Price Control Order (DPCO), 1995
    • 3.3.7 Indian Patent Act 1970
    • 3.3.8 The Drugs Price Control Order (DPCO), 2013
    • 3.3.9 Good Clinical Practices (GCP)
    • 3.3.10 Good Laboratory Practices (GLP)
  • 3.4 Market Access
    • 3.4.1 Healthcare System
    • 3.4.2 Status of Health Technology Assessment (HTA)
    • 3.4.3 Pricing
    • 3.4.4 Reimbursement of Drugs

4. Indian Pharmaceutical Market: Discussions and Predictions 2019-2029

  • 4.1 Indian Pharmaceutical Market: The Third Biggest Market in the World by Volume
  • 4.2 Indian Pharmaceuticals Market: Overall Revenue Forecast 2018-2029

5. Medical Treatment Needs in India, 2019-2029

  • 5.1 Disease Prevalence in India, 2019-2029
  • 5.2 Disease Incidence in India, 2019-2029
  • 5.3 Disease Mortality Rates in India, 2019-2029
    • 5.3.1 Top Causes of Death in India
    • 5.3.2 Top Causes of Death in India: Mortality Projections, 2019-2029

6. Indian Pharmaceutical Market: Leading Therapeutic Areas, 2019-2029

  • 6.1 Leading Therapeutic Areas in the Indian Pharmaceutical Market: Overview, 2018
  • 6.2 Indian Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2019-2029
  • 6.3 Infectious Disease Drugs: Overview, 2018
    • 6.3.1 Infectious Disease Drugs Market: Forecast, 2019-2029
    • 6.3.2 Diarrheal Diseases Responsible for Over Half a Million Annual Deaths, 2018
    • 6.3.3 Lower Respiratory Tract Infections Among Leading Causes of Death
    • 6.3.4 Tuberculosis Still Rife in India
    • 6.3.5 Malaria, Risk and Opportunity
    • 6.3.6 HIV in India: Growing Therapeutic Area Worth Watching
    • 6.3.7 Drivers and Restraints for the Infectious Diseases Pharmaceutical Segment
  • 6.4 Cardiovascular Therapeutics Segment: Overview, 2018
    • 6.4.1 Cardiovascular Disease - India's Leading Cause of Death, 2018
    • 6.4.2 Cardiovascular Drugs Market: Forecast, 2019-2029
  • 6.5 Gastro-Intestinal Therapeutic Segment: Overview, 2018
    • 6.5.1 Gastro-Intestinal Drugs Market: Forecast, 2019-2029
    • 6.5.2 Gastro-Intestinal Therapeutics in India: Challenges and Opportunities
    • 6.5.3 Drivers and Restraints for the Gastro-Intestinal Therapeutics Segment
  • 6.6 Respiratory Therapeutic Segment: Overview, 2018
    • 6.6.1 Respiratory Disease Drugs Market: Forecast, 2019-2029
    • 6.6.2 Drivers and Restraints for the Respiratory Therapeutics Segment
  • 6.7 Pain Relief / Analgesics Therapeutic Segment: Overview, 2018
    • 6.7.1 Pain Relief / Analgesics Drugs Market: Forecast, 2019-2029
    • 6.7.2 Drivers and Restraints for the Pain Relief/Analgesics Therapeutics Segment
  • 6.8 Diabetes Therapeutic Segment: Overview, 2018
    • 6.8.1 Diabetes Therapeutics Market: Forecast, 2019-2029
    • 6.8.2 Drivers and Restraints for the Diabetes Therapeutics Segment
  • 6.9 Vitamins / Minerals / Nutrients Therapeutic Segment: Overview, 2018
    • 6.9.1 Vitamins / Minerals / Nutrients Therapeutics Market: Forecast, 2019-2029
    • 6.9.2 Vitamins / Minerals / Nutrients in India: Challenges and Opportunities
    • 6.9.3 Drivers and Restraints for the Vitamins / Minerals / Nutrients Therapeutics Segment
  • 6.10 Dermatological Therapeutic Segment: Overview, 2018
    • 6.10.1 Dermatological Therapeutics Market: Forecast, 2019-2029
    • 6.10.2 Drivers and Restraints for the Dermatological Therapeutics Segment
  • 6.11 Central Nervous System (CNS) Therapeutics: Overview, 2018
    • 6.11.1 CNS Drugs Market: Forecast, 2019-2029
    • 6.11.2 Intentional Injury Among the Top 10 Leading Causes of Death, 2018
    • 6.11.3 India's Aging Population: Driver for the CNS Segment
    • 6.11.4 Drivers and Restraints for the CNS Therapeutics Segment
  • 6.12 Gynaecological Treatment Market Overview: 2018
    • 6.12.1 Infant Mortality Still High in India
    • 6.12.2 Indian Gynaecological Treatments Market: Forecast, 2019-2029
    • 6.12.3 Drivers and Restraints for the Gynaecological Segment
  • 6.13 Other Pharmaceutical Products Market Overview: 2018
    • 6.13.1 Incidence of Cancer is Rising in India
    • 6.13.2 Indian Other Treatments Market: Forecast, 2019-2029

7. Indian Pharmaceutical Market: Leading Drug Types, 2019-2029

  • 7.1 Drug Types in the Indian Market: Overview, 2018
  • 7.2 Growth Forecasts for Leading Drug Types in India, 2019-2029
  • 7.3 Generic Drugs Dominate the Indian Pharmaceutical Market
    • 7.3.1 Indian Generics: Overview, 2018
    • 7.3.2 Indian Generic Drugs Market: Forecast, 2018-2029
    • 7.3.3 Branded Generics Preferred by Many Indian Patients
    • 7.3.4 Drivers and Restraints for the Generic Drug Market in India
  • 7.4 Indian Over-The-Counter (OTC) Drugs Market: Overview, 2018
    • 7.4.1 Indian OTC Market: Forecast, 2019-2029
    • 7.4.2 Drivers and Restraints of the Indian OTC Market
  • 7.5 Indian Patented Drugs Market: Overview, 2018
    • 7.5.1 Indian Patented Drugs Market: Forecasts, 2019-2029
    • 7.5.2 Drivers and Restraints for the Indian Patented Drugs Market
  • 7.6 Indian Biosimilar Drugs, 2018
    • 7.6.1 Indian Biosimilar Drugs Market: Forecast, 2019-2029
    • 7.6.2 A Number of Blockbuster Drugs Coming Off-Patent Over the Next Decade
    • 7.6.3 Drivers and Restraints of the Indian Biosimilar Drugs Market

8. The Leading Companies in the Indian Pharmaceuticals Market

  • 8.1 Indian Pharmaceuticals Market Overview
    • 8.1.1 Indian Pharmaceutical Patent Law and the Effect on Big Pharmaceutical Companies
  • 8.2 Top 50 Domestic Indian Pharmaceutical Companies, 2018
  • 8.3 Sun Pharmaceuticals Industries Limited
    • 8.3.1 Sun Pharma: Global Presence
      • 8.3.1.1 Sun Pharmaceutical Sales by Region, 2017
    • 8.3.2 Sun Pharmaceuticals Business Performance 2008-2017
    • 8.3.3 Sun Pharmaceutical: The Acquisition of Ranbaxy Laboratories is the Largest Ever Deal Made by an Indian Pharmaceutical Company
      • 8.3.3.1 Other Major M&A Activity
  • 8.4 Abbott Healthcare Private Limited (Abbott India)
    • 8.4.1 Abbott India: Business Performance 2007-2017
    • 8.4.2 Abbott India: Major and Recent M&A Activity
  • 8.5 Cipla Ltd.
    • 8.5.1 Cipla: Business Performance 2008-2017
    • 8.5.2 Cipla Ltd.: Major and Recent Activity
  • 8.6 Cadila Healthcare Limited
    • 8.6.1 Cadila: Business Performance 2008-2017
    • 8.6.2 Cadila Healthcare Revenue by Therapeutic Area 2017
  • 8.7 GlaxoSmithKline Pharmaceuticals Limited
    • 8.7.1 GlaxoSmithKline India: Business Performance 2008-2017
  • 8.8 Pfizer Limited., India
    • 8.8.1 Pfizer India: Business Performance 2008-2017
  • 8.9 Lupin
    • 8.9.1 Lupin: Business Performance 2008-2017
    • 8.9.2 Lupin Revenue by Therapeutic Area, 2017
  • 8.10 Sanofi India Limited
    • 8.10.1 Sanofi India Limited: Business Performance 2008-2017
    • 8.10.2 Sanofi India Limited Revenue by Business Segments, 2017
    • 8.10.3 Sanofi India Limited Revenue by Geographical Area, 2017
    • 8.10.4 Sanofi India Limited Recent Activities
  • 8.11 Intas Pharmaceuticals Limited
    • 8.11.1 Intas Pharmaceuticals Limited: Business Performance 2008-2017
  • 8.12 Dr. Reddy's Laboratories Ltd.
    • 8.12.1 Dr. Reddy's Laboratories Ltd: Business Performance 2008-2017
    • 8.12.2 Dr. Reddy's Laboratories Ltd. Revenue by Business Segments, 2017
    • 8.12.3 Dr. Reddy's Laboratories Ltd Global Generics Segment Revenue by Geographical Area, 2017
  • 8.13 Glenmark Pharmaceuticals Limited
    • 8.13.1 Glenmark Pharmaceuticals Limited: Business Performance 2008-2017
    • 8.13.2 Glenmark Pharmaceuticals Limited Revenue by Geographical Area, 2017
    • 8.13.3 Glenmark Pharmaceuticals Limited Recent Activities

9. Qualitative Analysis of the Indian Pharmaceuticals Market, 2018

  • 9.1 Indian Pharmaceutical Market: Drivers and Restraints
  • 9.2 SWOT Analysis of the Indian Pharmaceuticals Market
  • 9.3 Strengths
    • 9.3.1 Increasing Investment in the Healthcare System
    • 9.3.2 The Disease Burden and GDP Growing
    • 9.3.3 India's Population Set to Become the World's Largest by 2030
    • 9.3.4 India Popular for Pharmaceutical Outsourcing
  • 9.4 Weaknesses
    • 9.4.1 Stringent Pricing Regulations Hit the Indian Pharmaceuticals Market
    • 9.4.2 Poor Infrastructure Threatens to Hinder Market Potential
    • 9.4.3 Intense Competition Driving Down Drug Prices
  • 9.5 Opportunities
    • 9.5.1 Global Demand for Generics Rising
    • 9.5.2 National Rural Health Mission Driving Healthcare Access in Rural Areas
    • 9.5.3 Significant Investment from MNCs Expected
    • 9.5.4 Innovative Biotechnology Sector Set to Capitalise on Patent Expiries
  • 9.6 Threats
    • 9.6.1 Rise of Other Low-Cost Generic Exporters
    • 9.6.2 Will the Indian Government Stick to Increasing Healthcare Expenditure?
    • 9.6.3 Recent Warnings and Export Bans from Regulatory Bodies Hit Confidence in Indian Pharmaceuticals
  • 9.7 Porter's Five Forces Analysis of the Indian Pharmaceuticals Market
    • 9.7.1 Rivalry Among Competitors [High]
    • 9.7.2 Threat of New Entrants [Low]
    • 9.7.3 Power of Suppliers [Medium]
    • 9.7.4 Power of Buyers [High]
    • 9.7.5 Threat of Substitutes [Low]

10. Conclusion

  • 10.1 The Indian Pharmaceuticals Market: Growing Global Market Share
  • 10.2 Indian Pharmaceutical Market: Chronic Diseases Becoming Increasingly Prevalent
  • 10.3 Commercial Drivers of the Indian Pharmaceuticals Market
  • 10.4 Commercial Restraints of the Indian Pharmaceuticals Market
  • 10.5 Concluding Remarks

11. Glossary

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form
Back to Top
전화 문의
F A Q